Joseph Aisner, MD Chief, Oncology; Associate Director for Clinical Science, CINJ; Co-Leader, Clinical Investigations Research Program Professor of Medicine and Environmental and Occupational Medicine Robert Wood Johnson Medical School Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901-1914 Phone: (732) 235-7401 Email: aisnerjo@umdnj.edu Assistant: Bernadette DeSouza (732) 235-7464 Email: desouzbe@umdnj.edu

Research Program Alignment

• Clinical Investigations Program

Membership Type: Full

Selected Publications

Fuks JZ, Aisner J, Van Echo DA, Schipper H, Levitt M, Ostrow S, Wiernik PH:  Randomized study of cyclophosphamide, adriamycin and etoposide (VP16-213) with or without cisplatin in non-small cell lung cancer.  J Clin Oncol 1983; 1:295-301.

Aroney RS, Dermody WC, Aldenderfer P, Parsons P, McNitt K, Marangos PS, Whitacre MY, Ruddon RW, Wiernik PH, Aisner J:  Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.  Cancer Treat Rep 1984; 68:859-866.

Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J: Pharmacokinetics and dosage reduction of cis-Diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function.  Cancer Research, 1984; 44:5432-5438.

Fuks JZ, Patel H, Van Echo DA, Hornedo J, Aisner J: Vindesine and high dose cisplatin in the treatment of advanced non-small cell lung cancer.  Med Ped Oncol, 1985; 13:73-77.

Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J: Prospective validation of a pharmacologically based dosing schema for the cisplatin analog, carboplatin.  Cancer Research, 1985; 45:6502-6506

Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL, Aisner J: Human pharmacokinetics, excretion and metabolism of the anthracycline antibiotic menogaril (NSC 269148, 7-OMEN) and their correlation with clinical toxicities.  Cancer Research, 1986, 46:1513-1520

Egorin MJ, Sigman LM, Van Echo DA, Forest A, Whitacre MY, Aisner J: A phase I clinical and pharmacokinetic study of hexamethylbis-acetamide (HMBA, NSC 95580) administered as a five day continuous infusion.  Cancer Research 47: 1987; 617-623.

Belani CP, Egorin MJ, Abrams JS, Hiponia D, Eisenberger M, Aisner J, Van Echo DA: A novel pharmacodynamically-based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncology, 1989; 7: 1896-1902

Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, Perry M: Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide Combination Chemotherapy for Small Cell Lung Cancer. Cancer Chemotherap Pharmacol, 1992; 29: 435-438.

Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. J Clin Oncol, 1999; 17:676-684.

Auperin A, Arriagada R, Pignon JP, Pechoux Cl, Gregor A, Sephens RJ, Kristjansen PEG, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic Cranial Irradiation for patients with small cell lung cancer in complete remission: A meta-analysis of individual data from 987 patients. N Engl J Med, 1999, 341:476-484.

Sovak MA, Lutzker S, Zheng L, Guensch L, Joyce M, Schwartz S, Wu Y, Aisner  J: Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer. Lung Cancer. 2006;53:177-81. Epub 2006 Jun 21.

Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH: Phase I evaluation of sequential opoisomerase targeting with irinotecan/cisplatin flowed by etoposide in patients with advanced malignancy. Clin Cancer Res. 2003, 9:1673-1679

Saraiya B, Gounder M, Dutta J, Saleem A, Collazo C, Zimmerman L, Nazar A, Gharibo M, Schaar D, Lin Y, Aisner J, Strair RK, Rubin EH: Sequential opoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticaner Drugs, 2008; 19:411-420

Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L: A Phase I study of weekly R1507 – A human monoclonal antibody Insulin-1 Growth Factor-1 receptor antagonist – in patients with advanced solid tumors Clinical Cancer Res 2010 16:2458-2465